Table 2 Structure of CBD analogs and summary of effect of modification to different positions on antimicrobial activity against MRSA and N. gonnorrhoeae (MIC, μg mL⁻¹, n = 4).

Control: Vancomycin

1

nd

Control: Colistin

nd

32

Control: Daptomycin

1–2

>64

Control: Clindamycin

>64

1

Control: Mupirocin

0.125–0.5

≤0.03–0.06

1

Cannabidiol

A

nPr

H

OH

OH

Me

1–2

0.125–2

2

7-hydroxycannabidiol

A

nPr

H

OH

OH

CH₂OH

16

0.25–2

3

MTC-005

A

nPr

H

OH

OH

CH₂OMe

16

4–16

4

7-nor-7-carboxycannabidiol

A

nPr

H

OH

OH

CO₂H

64–>64

0.5–2

5

MTC-002

A

nPr

H

OH

OH

CONHMe

16

2–4

6

Cannabidivarin

A

Me

H

OH

OH

Me

2–4

≤0.03–0.5

7

7-nor-7-hydroxymethyl-cannabidivarin

A

Me

H

OH

OH

CH₂OH

64

>64

8

7-nor-7-carboxy-cannabidivarin

A

Me

H

OH

OH

CO₂H

>64

2–16

9

MTC-007

A

nPent

H

OH

OH

Me

0.5–2

0.5–4

10

MTC-017

A

(CH₂)₂Ph

H

OH

OH

Me

2

0.5–4

11

MTC-011

A

nPr

H

H

OH

Me

64–>64

1–8

12

MTC-012

A

nPr

H

OMe

OH

Me

>64

8–32

13

MTC-013

A

nPr

H

OMe

OMe

Me

>64

>64

14

Cannabidiolic acid (CBDA)

A

nPr

CO₂H

OH

OH

Me

16–32

1–2

15

MTC-018

B

nPent

–

–

–

–

1–2

1–2

16

MTC-008

B

(CH₂)₂Ph

–

–

–

–

2–4

1–4

17

MTC-014

C

–

–

–

–

–

0.25–0.5

0.25–0.5

18

MTC-009

D

–

–

–

–

–

1–2

0.5–2

19

Tetrahydrocannabivarin (THCV)

E

Me

H

–

–

–

64

16

20

Tetrahydrocannabivarinic acid (THCVA)

E

Me

CO₂H

–

–

–

32–64

4–16

21

(−)-Δ⁹-THC

E

nPr

H

–

–

–

4–8

4–8

22

Δ⁹-tetrahydrocannabinolic acid A (THCA-A)

E

nPr

CO₂H

–

–

–

8

0.5–8

23

(−)-Δ⁸-THC

F

–

–

–

–

–

4–8

2–4

24

Cannabinolic acid A (CBNA)

G

–

–

–

–

–

4–16

0.25–4

25

Cannabigerol (CBG)

H

–

H

–

–

–

4–8

1–2

26

Cannabigerolic acid (CBGA)

H

–

CO₂H

–

–

–

2–4

1–2